Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arterra Bioscience SpA's ROE % for the quarter that ended in Dec. 2025 was 15.20%. Arterra Bioscience SpA's PB Ratio for the quarter that ended in Dec. 2025 was 1.56.
Arterra Bioscience SpA's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 9.74%.
Arterra Bioscience SpA ROE % Adjusted to Book Value Related Terms
Arterra Bioscience SpA ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Arterra Bioscience SpA's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arterra Bioscience SpA ROE % Adjusted to Book Value Chart
MIL:ARBS vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Arterra Bioscience SpA's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arterra Bioscience SpA ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arterra Bioscience SpA's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Arterra Bioscience SpA's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 9.74% mean?
Arterra Bioscience SpA (MIL:ARBS) has a ROE % Adjusted to Book Value of 9.74% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Arterra Bioscience SpA and its competitors.
Is Arterra Bioscience SpA's ROE % Adjusted to Book Value too high?
Arterra Bioscience SpA's current ROE % Adjusted to Book Value is 9.74%. Overall, Arterra Bioscience SpA has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arterra Bioscience SpA's ROE % Adjusted to Book Value compare to VRTX and REGN?
Arterra Bioscience SpA's ROE % Adjusted to Book Value of 9.74% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Arterra Bioscience SpA and its competitors. Arterra Bioscience SpA's current ROE % Adjusted to Book Value is 9.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arterra Bioscience SpA stock overvalued right now?
Based on GuruFocus' analysis, Arterra Bioscience SpA (MIL:ARBS) is currently considered Fairly Valued. The stock's GF Value™ is €2.91, compared to a current price of €3.04 — trading 4.5% above its estimated fair value. The current ROE % Adjusted to Book Value is 9.74%. Arterra Bioscience SpA's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Arterra Bioscience SpA (MIL:ARBS), the current ROE % Adjusted to Book Value is 9.74% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arterra Bioscience SpA (MIL:ARBS) Overvalued in 2026?
Based on GuruFocus' analysis, Arterra Bioscience SpA stock appears to be overvalued.
The current stock price of €3.04 is trading 4.5% above its estimated GF Value™ of €2.91.
GuruFocus considers Arterra Bioscience SpA to be Fairly Valued.
Key valuation signals for MIL:ARBS:
ROE % Adjusted to Book Value: 9.74%
GF Value™: €2.91 vs. price of €3.04 (4.5% above fair value)
No single metric tells the full story. See the MIL:ARBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
77GF Score
Get the complete analysis for MIL:ARBS
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ARBS has been successfully added to your 
